期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Safety of endovascular therapy for symptomatic intracranial artery stenosis:a national prospective registry 被引量:3
1
作者 Yabing Wang Tao Wang +29 位作者 Adam Andrew Dmytriw Kun Yang Liqun Jiao Huaizhang Shi Jie Lu Tianxiao Li Yujie Huang Zhenwei Zhao Wei Wu Jieqing Wan Qinjian Sun Bo Hong Yongli Li Liyong Zhang Jianfeng Chu Qiong Cheng Yiling Cai Pengfei Wang Qi Luo Hua Yang Baijing Dong Yang Zhang Jun Zhao Zuoquan Chen Wei Li Xiaoxin Bai Weiwen He Xueli Cai Maimai Ti Osama O Zaidat 《Stroke & Vascular Neurology》 SCIE CSCD 2022年第2期166-171,共6页
Introduction The safety outcomes of endovascular therapy for intracranial artery stenosis in a real-world stetting are largely unknown.The Clinical Registration Trial of Intracranial Stenting for Patients with Symptom... Introduction The safety outcomes of endovascular therapy for intracranial artery stenosis in a real-world stetting are largely unknown.The Clinical Registration Trial of Intracranial Stenting for Patients with Symptomatic Intracranial Artery Stenosis(CRTICAS)was a prospective,multicentre,real-world registry designed to assess these outcomes and the impact of centre experience.Methods 1140 severe,symptomatic intracranial arterial stenosis(ICAS)patients treated with endovascular therapy were included from 26 centres,further divided into three groups according to the annual centre volume of intracranial angioplasty and stent placement procedures over 2 years:(1)high volume for≥25 cases/year;(2)moderate volume for 10–25 cases/year and(3)low volume for<10 cases/year.Results The rate of 30-day stroke,transient ischaemic attack or death was 9.7%(111),with 5.4%,21.1%and 9.7%in high-volume,moderate-volume and low-volume centres,respectively(p<0.05).Multivariable logistic regression confirmed high-volume centres had a significantly lower primary endpoint compared with moderate-volume centres(OR=0.187,95%CI:0.056 to 0.627;p≤0.0001),while moderate-volume and low-volume centres showed no significant difference(p=0.8456).Conclusion Compared with the preceding randomised controlled trials,this real-world,prospective,multicentre registry shows a lower complication rate of endovascular treatment for symptomatic ICAS.Non-uniform utilisation in endovascular technology,institutional experience and patient selection in different volumes of centres may have an impact on overall safety of this treatment. 展开更多
关键词 INTRACRANIAL PROSPECTIVE STENOSIS
原文传递
端粒酶活性及其结构基因在人脑胶质瘤中的表达 被引量:2
2
作者 刘平 LU Yicheng +3 位作者 卢亦成 袁国梁 朱诚 夏放 《中华实验外科杂志》 CAS CSCD 北大核心 2001年第2期147-149,共3页
目的 研究分析端粒酶活性及相关结构基因在不同级别脑胶质瘤中的表达 ,探讨端粒酶与脑胶质瘤的相关性及其临床意义。方法 采集 40例脑胶质瘤手术切除标本、4例正常脑组织 ,通过半定量端粒重复序列扩增 (TRAP) 银染方法检测端粒酶活... 目的 研究分析端粒酶活性及相关结构基因在不同级别脑胶质瘤中的表达 ,探讨端粒酶与脑胶质瘤的相关性及其临床意义。方法 采集 40例脑胶质瘤手术切除标本、4例正常脑组织 ,通过半定量端粒重复序列扩增 (TRAP) 银染方法检测端粒酶活性水平 ;通过半定量逆转录 聚合酶链反应 (RT PCR)检测端粒酶相关结构基因hTR、TP1、hTRT的mRNA表达水平。结果 在40例胶质瘤标本的 3 3例 (82 .5 % )中检测出端粒酶活性 ,而在正常脑组织中无端粒酶活性的表达 ,不同级别脑胶质瘤之间端粒酶活性水平差异有显著性 ,脑胶质瘤端粒酶活性水平与hTRT基因的表达呈显著正相关 ,而与TP1、hTR的表达无显著相关。结论 端粒酶活性可以作为脑胶质瘤的恶性标记之一 ,hTRT基因是一个端粒酶的正调控结构基因 ,hTRT的表达与细胞永生化和恶性肿瘤形成过程中的端粒酶的激活机制有关 ,hTR基因是端粒酶活性必须的组分 。 展开更多
关键词 端粒 末端转移酶 神经胶质瘤 脑胶质瘤 基因表达
原文传递
Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study 被引量:40
3
作者 JIANG Tao TANG Gen-fu +11 位作者 LIN Yi PENG Xiao-xia ZHANG Xiao ZHAI Xiu-wei PENG Xiang YANG Jin-qing HUANG Hong-er WU Nai-feng CHEN Xiao-jun XING Hou-xun SU Tong-yong WANG Zhong-cheng 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第17期2578-2583,共6页
Background Although the first leading cause of death in China was malignant neoplasms (mortality, 374.1 per 100 000 person-years), the full impact of primary brain tumors (PBT) on the healthcare system is not comp... Background Although the first leading cause of death in China was malignant neoplasms (mortality, 374.1 per 100 000 person-years), the full impact of primary brain tumors (PBT) on the healthcare system is not completely described because there are a few well documented reports about the epidemiologic features of brain tumors. This study aimed to report a comprehensive assessment on the prevalence of PBT. Methods A multicenter cross-sectional study on brain tumor (MCSBT) in China was initiated in five regional centers: Daqing (northeast), Puyang (north of China), Shiyan (center of China), Ma'anshan (center of China) and Shanghai (southeast). Prevalence rate was calculated by counting the number of people living with a PBT between October 1,2005 and September 30, 2006 and dividing by the total population of the five communities at January 1, 2006. Estimates of prevalence were expressed as percentages and grouped according to gender and to age in fifteen-year categories. Within these strata, the rates were estimated with 95% confidence intervals (C/) using the accurate calculation of CI for Poisson distribution. A chi-square test was used to compare the various frequencies with a 〈0.05. Age-standardized prevalence with the direct method was calculated with the ten-year age-specific prevalence and the age distribution of population prospects: the 2008 revision. Results We estimated that the overall prevalence of PBT was 24.56 per 100 000 (95% CI, 14.85 to 34.27), and the overall prevalence of PBT in female population (30.57 per 100 000 and its 95% Cl ranged from 19.73 to 41.41) was higher than that in male population (18.84 per 100 000 and its 95% Cl ranged from 10.33 to 27.35). However, the discrepancy between genders was not statistically significant because the 95% Cl overlapped. Of 272 cases of newly diagnosed PBT, the proportion of histological subtypes by age groups, gender was statistically different (X2=52.6510, P 〈0.0001). More than half of all reported tumors (52.57%) were either gliomas or meningiomas. For the youngest (aged from 0-19) strata of the population, glioma appeared to occur more than other subtypes, accounting for 55.56% of all of cases. The majority of brain tumors presented in those aged from 20 to 59 years was pituitary adenomas (45.12%) and gliomas (31.10%). Opposed to brain tumors in adults and teenage, gliomas only accounted for 22.22%. Meanwhile, the median ages at diagnosis of the patients with PBT were similar between males and females except for pituitary adenomas (male: 59 years old; female: 45 years old). Conclusions Age standardized prevalence of PBT is 22.52 per 100 000 (95% CI, 13.22 to 31.82) for all populations, 17.64 per 100 000 (95% CI, 9.41 to 25.87) for men, and 27.94 per 100 000 (95% Cl, 17.58 to 38.30) for women. Age standardization to China's 2010 population yielded an estimated population of 304 954 cases with PBT. Our prevalence estimates provide a conservative basis on which to plan health care services and to develop programmatic strategies for surviving. Inthe future, it would be helpful to have long-term observed survival rates that would make the assumptions and the resulting imprecision in the current estimates unnecessary. 展开更多
关键词 primary brain tumors PREVALENCE multicenter cross-sectional study
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部